Photobiomodulation using red and infrared spectrum light emitting-diode (LED) for the healing of diabetic foot ulcers: a controlled randomized clinical trial

What the authors concluded

Red and infrared LEDs were used, at the wavelengths 620 nm (G-LED V) and 940 nm (G-LED IV), as well as at an associated way 620 nm + 940 nm (G-LED A)." "However, according to Cohen’s d classification of magnitudes of clinical effect [32], at the pre vs. post intervention time of 90 days, we found a “large clinical effect” of G-LED V (d = 1.7) and G -LED IV (d = 1.6) in relation to G-C, where the

Devices that emit this wavelength

Matched on wavelength within 15nm, since LED bins vary by roughly that much and a tighter match would be false precision. Where we have an irradiance figure, the session length is the time needed to reach this study's dose of 6 J/cm² at that intensity.

Matching a wavelength is not the same as reproducing a trial. Session times assume the device's published irradiance is accurate at the distance it was measured, which on brand-claim figures is often optimistic. Where a device publishes both a peak and an average we use the average, and where it publishes a falloff curve we use the lowest figure, so these times run long rather than short. Clinical protocols also control for spot size, contact and skin type in ways a home device cannot.